Singapore markets closed
Straits Times Index
3,290.70 +24.75 (+0.76%) Nikkei
38,229.11 +155.13 (+0.41%) Hang Seng
18,963.68 +425.87 (+2.30%) FTSE 100
8,433.76 +52.41 (+0.63%) Bitcoin USD
61,108.84 +667.10 (+1.10%) CMC Crypto 200
1,261.13 -96.88 (-7.13%)
Phio Pharmaceuticals Corp. (PHIO)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 0.7700 |
| Open | 0.7500 |
| Bid | 0.6756 x 100 |
| Ask | 0.7456 x 100 |
| Day's range | 0.6912 - 0.7800 |
| 52-week range | 0.5000 - 6.8500 |
| Volume | |
| Avg. volume | 422,125 |
| Market cap | 3.235M |
| Beta (5Y monthly) | 1.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
PHIO Jumps 91% on Encouraging Preclinical Cancer Drug Data
Data from preclinical studies show that Phio's (PHIO) cancer drug PH-894 is effective in BRD4 inhibition for treating various cancer indications like melanoma, breast cancer and lung cancer.
- Zacks
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.
© 2024 Yahoo. All rights reserved.